Altasciences Initiates Phase I Study in Healthy Normal Subjects for ST-2427, a Non-Opioid Analgesic for Acute Pain
13.5.2021 19:31:00 EEST | Business Wire | Press release
Altasciences is pleased to support SiteOne Therapeutics with a Phase I, randomized, double-blind, placebo-controlled study in healthy adults to evaluate the safety, tolerability, and pharmacokinetics of ST-2427. ST-2427 is a highly selective inhibitor of NaV1.7 for the management of moderate-to-severe pain; by selectively targeting NaV1.7, ST-2427 aims to stop the electrical signals responsible for pain before they reach the central nervous system.
Amy Denvir, General Manager of Altasciences’ Kansas City clinical site, says, “We are proud to partner with SiteOne Therapeutics and help move this important therapeutic into clinical trials. Helping bring to market a new approach that may provide a non-opioid option to treat moderate- to-severe pain is an exciting prospect, and we look forward to delivering this ground-breaking research.”
Click here to read the SiteOne press release.
Altasciences has designed and conducted hundreds of first-in-human trials by offering comprehensive, full service, early development solutions. With a focus on developing sound strategies combined with operational efficiencies, the company minimizes the time taken to make critical go/no-go decisions by harmonizing clinical pharmacology services, biomarker capabilities, PK/PD analysis expertise, and program knowledge.
About Altasciences
Altasciences is an integrated drug development solution company offering pharmaceutical and biotechnology companies a proven, flexible approach to preclinical and clinical pharmacology studies, including formulation, manufacturing, and analytical services. For over 25 years, Altasciences has been partnering with sponsors to help support educated, faster, and more complete early drug development decisions. Altasciences’ integrated, full-service solutions include preclinical safety testing, clinical pharmacology and proof of concept, bioanalysis, program management, medical writing, biostatistics, clinical monitoring, and data management, all customizable to specific sponsor requirements. Altasciences helps sponsors get better drugs to the people who need them, faster.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210513005827/en/
Contact information
Julie-Ann Cabana
Altasciences
+1 514 601-9763
jcabana@altasciences.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Compvide ™ Announces Strategic Collaboration with OpZira ™ to Accelerate Growth and Advance the CIMED ™ Platform16.7.2026 13:47:00 EEST | Press release
Compvide, Inc., a biotechnology company pioneering functional complement intelligence through innovative diagnostics and immune-response monitoring, today announced a strategic collaboration with OpZira, Inc. to support the company’s continued growth and accelerate development of its proprietary CIMED platform. Through the collaboration, OpZira will provide comprehensive operational support across clinical, customer care, finance, manufacturing, marketing, quality, and regulatory functions,” stated Clark Tedford, Ph.D., President and CEO, OpZira, Inc. “By leveraging OpZira’s established operational infrastructure and expertise, Compvide can remain focused on advancing its scientific innovation while expanding its capabilities in complement-focused diagnostics and translational medicine.” “Partnering with an experienced organization that understands the unique needs of emerging healthcare companies is an important step for Compvide as we continue building the company,” said Sadam Yaseen
Compass Pathways Announces Publication of Post-Hoc Analysis Demonstrating Distinction of COMP360 Trial Monitoring & Support from Psychotherapy16.7.2026 13:35:00 EEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the publication of a post-hoc analysis of support methods used in an open-label Phase 2 study of investigational COMP360 synthetic psilocybin treatment in patients with post-traumatic stress disorder (PTSD). Documented speech production between participants and support providers during treatment administration sessions showed minimal interaction. Monitoring and support were linked by patients to presence, availability, reassurance and validation. The limited and non-directive nature of these interactions distinguishes this form of support from therapeutic dialogues typically used in conventional psychotherapy or other trauma-focused psychological treatments. “The monitoring and support we’ve incorporated across our COMP360 trials in both treatment-resistant depression and PTSD is designed to safeguard patients and protect d
Circus Commences Operations with Ukrainian Ground Forces16.7.2026 13:04:00 EEST | Press release
Circus SE (WKN: A2YN35 / ISIN: DE000A2YN355 / XETRA: CA1), today announces the commencement of live operations of its robotic-based troop supply technology with the 3rd Army Corps of the Ukrainian Ground Forces in the Kyiv area – marking the first ever use of autonomous meal supply systems within an active conflict environment. Ahead of deployment, Circus received regulatory certification from the State Service of Ukraine for Food Safety and Consumer Protection. This certification confirms compliance with all applicable health, quality, and safety standards required to import the company's technology into Ukraine, and clears the path for operational use at scale. Soldiers are supplied using Circus's full technology stack, comprising the hardware system, AI-controlled software, and proprietary ingredient infrastructure that underpins autonomous meal production in military environments. The deployment marks Circus's entry into the Ukrainian market and the operational commencement of the
Fourthline and Veridas Join Forces to Fight Identity Fraud with a Global Identity Platform16.7.2026 12:21:00 EEST | Press release
Fourthline, Europe's identity verification and compliance leader, has signed an agreement to merge with Veridas, a recognised international digital identity provider, to deliver the most complete and advanced trust platform across Europe and the Americas. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629494028/en/ Paul Stoddart, CEO of Fourthline The combination unites Fourthline's institutional-grade KYC/AML compliance orchestration across Northern and Central Europe with Veridas's proprietary identity and anti-fraud stack and market position in Southern Europe, the US, and Latin America. Operating under a single, integrated AI architecture, the combined entity will secure the entire customer lifecycle for global Tier-1 banks, fintechs, telecommunications providers, and digital disruptors across both continents. Fourthline and Veridas come together from a position of strength, both profitable, EBITDA-positive, and at th
Tax Systems Rebrands as Alphatax16.7.2026 11:00:00 EEST | Press release
Tax Systems, a global tax and accounting software provider, today announced it is rebranding as Alphatax, aligning the company with its flagship corporation tax compliance solution and marking the next stage in its evolution as an AI-first technology business. The rebrand reflects the company's ambition to redefine how tax professionals work through connected, AI-powered technology. As Alphatax, the business is bringing together compliance, data, governance and intelligence into a single platform, creating the foundations for the world’s first tax operating system: a connected environment where tax data, decisions, approvals, filings and evidence can come together. The new identity builds on the strong reputation of Alphatax, a market-leading corporation tax software trusted by tax professionals across the world. Bringing the company’s expanding portfolio together under one master brand will provide customers with a more connected experience across corporate tax, Pillar Two, transfer p
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom